ovidius. I respectfully disagree. Management timeline has been off but they have plugged along. They have spent next to nothing. And if you don't understand that - look at any other biotech in its early stages. Ovidius you shorters are picking on the wrong stock. Yes it looks vulnerable but if you understand the science behind it - it is one of the surest things for a biotech stocks I have ever seen. Be very careful.
And also you call this a company a lifestyle company for Dr. Seymour. (or something like that) Believe me - Dr. Seymour wants one thing. A grand slam! A billion dollar plus lifestyle
Market Data 
Markets 
AI
